Ovid Therapeutics Inc (OVID) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ovid Therapeutics Inc (OVID) has a cash flow conversion efficiency ratio of -0.080x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.41 Million) by net assets ($130.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ovid Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Ovid Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Ovid Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ovid Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ovid Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thaicom Public Company Limited
BK:THCOM
|
0.017x |
|
Beijing Bashi Media Co Ltd
SHG:600386
|
0.071x |
|
Guangdong Guanghong Holdings Co Ltd
SHE:000529
|
-0.001x |
|
Richtech Robotics Inc. Class B Common Stock
NASDAQ:RR
|
-0.005x |
|
Soltec Power Holdings S.A
MC:SOL
|
0.089x |
|
Bafang Yunji Intl Co Ltd
TW:2753
|
0.123x |
|
Duni AB
ST:DUNI
|
-0.029x |
|
Taiwan Navigation Co Ltd
TW:2617
|
0.046x |
Annual Cash Flow Conversion Efficiency for Ovid Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Ovid Therapeutics Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see OVID market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.66 Million | $-38.33 Million | -0.293x | +64.23% |
| 2024-12-31 | $68.23 Million | $-55.96 Million | -0.820x | -57.29% |
| 2023-12-31 | $87.80 Million | $-45.78 Million | -0.521x | -24.89% |
| 2022-12-31 | $132.27 Million | $-55.23 Million | -0.418x | -163.27% |
| 2021-12-31 | $179.75 Million | $118.61 Million | 0.660x | +155.82% |
| 2020-12-31 | $43.63 Million | $-51.58 Million | -1.182x | -62.04% |
| 2019-12-31 | $70.02 Million | $-51.09 Million | -0.730x | +37.85% |
| 2018-12-31 | $38.81 Million | $-45.56 Million | -1.174x | -211.27% |
| 2017-12-31 | $83.44 Million | $-31.47 Million | -0.377x | -4.44% |
| 2016-12-31 | $49.29 Million | $-17.80 Million | -0.361x | -348.12% |
| 2015-12-31 | $68.07 Million | $-5.49 Million | -0.081x | -46.14% |
| 2014-12-31 | $4.74 Million | $-261.28K | -0.055x | -- |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human or… Read more